Larimar Therapeutics Inc is a pioneering biotechnology firm based in Bala Cynwyd, Pennsylvania, dedicated to creating innovative treatments for rare diseases. With a focus on leveraging its unique cell penetrating peptide technology, Larimar is at the forefront of research and development. Its flagship project, CTI-1601, is currently undergoing Phase 2 clinical trials aimed at combating Friedreich’s ataxia, a devastating and life-shortening genetic disorder. This commitment to addressing unmet medical needs highlights Larimar's role in the quest for groundbreaking therapeutic solutions.
Berkshire Hathaway has resumed acquiring shares of Warren Buffett's favorite media stock. Other insider buyers are focused on three biotech stocks.
